The Size of the Asia Pacific Cardiac Marker Testing Market is expected to grow at 11.7% CAGR from 2019 to 2024 and it is projected that the market is valued at USD 0.44 billion in 2019 and is anticipated to reach USD 0.76 billion by 2024.
Factor such as an increase in the incidence and occurrences of cardiovascular diseases is among the main factors driving the market growth. Furthermore, a number of factors such as growing instances of cardiovascular diseases, the rapidly increasing geriatric population, growing to fund from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimburse schemes are expected to hinder the growth of the market.
In addition to this, public-private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars are the key factors propelling the demand for cardiac biomarkers in the emerging markets.
The Asia-pacific market is expected to register the highest growth. Emerging markets, including India and China, have become attractive destinations for companies engaged in the development and marketing of cardiac biomarkers. Rising prevalence and incidence of cardiovascular diseases are among the major driving factors for the growth of this market in China and India.
For instance, annual cardiovascular events in China were projected to increase by more than 50% from 2010 to 2030. China has one of the highest CVD death rates in the world and it is estimated that one in 5 adults in China has cardiovascular disease.
Asia Pacific Cardiac Marker Testing Market has been segmented and sub-segmented into the following categories
Top Companies leading the Asia Pacific Cardiac Marker Testing Market Profiled in the report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Reagents and Kits
5.1.3 Instruments
5.1.3.1 Chemiluminescence
5.1.3.2 Immunofluorescence
5.1.3.3 Elisa
5.1.3.4 Immunochromatography
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Troponin I & T
5.2.3 CK-MB
5.2.4 Myoglobin
5.2.5 BNP
5.2.6 hsCRP
5.2.7 Y-o-Y Growth Analysis, By Type
5.2.8 Market Attractiveness Analysis, By Type
5.2.9 Market Share Analysis, By Type
5.3 Disease
5.3.1 Introduction
5.3.2 Acute Coronary Syndrome
5.3.3 Myocardial Infarction
5.3.4 Congestive Heart Failure
5.3.5 Y-o-Y Growth Analysis, By Disease
5.3.6 Market Attractiveness Analysis, By Disease
5.3.7 Market Share Analysis, By Disease
5.4 Type of Testing
5.4.1 Introduction
5.4.2 Lab
5.4.3 Point-Of-Care Testing
5.4.4 Y-o-Y Growth Analysis, By Type of Testing
5.4.5 Market Attractiveness Analysis, By Type of Testing
5.4.6 Market Share Analysis, By Type of Testing
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Disease
6.1.3.5 By Type of Testing
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Disease
6.1.4.5 By Type of Testing
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Disease
6.1.5.5 By Type of Testing
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of APAC
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Getinge Group
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Medtronic plc
8.3 LivaNova PLC
8.4 XENIOS Roche Diagnostics Ltd.
8.5 Abbott Laboratories
8.6 Siemens AG
8.7 Danaher Corporation
8.8 Alere Inc.
8.9 BioMérieux SA
8.10 LSI Medience Corporation
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
